• Something wrong with this record ?

Six-month electrical performance of the first dual-chamber leadless pacemaker

G. Hindricks, R. Doshi, P. Defaye, DV. Exner, VY. Reddy, RE. Knops, R. Canby, M. Shoda, MG. Bongiorni, P. Neužil, T. Callahan, S. Sundaram, N. Badie, JE. Ip

. 2024 ; 21 (10) : 1929-1938. [pub] 20240430

Language English Country United States

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc25004081

BACKGROUND: The first dual-chamber leadless pacemaker (DC-LP) system consists of 2 separate atrial and ventricular devices that communicate to maintain synchronous atrioventricular pacing and sensing. The initial safety and efficacy were previously reported. OBJECTIVE: The purpose of this study was to evaluate the chronic electrical performance of the DC-LP system. METHODS: Patients meeting standard dual-chamber pacing indications were enrolled and implanted with the DC-LP system (Aveir DR, Abbott), including right atrial and ventricular helix-fixation LPs (atrial leadless pacemaker [ALP], ventricular leadless pacemaker [VLP]). Pacing capture threshold, sensed amplitude, and pacing impedance were collected using the device programmer at prespecified timepoints from 0-6 months postimplant. RESULTS: De novo devices were successfully implanted in 381 patients with complete 6-month data (62% male; age 69 ± 14 years; weight 82 ± 20 kg; 65% sinus nodal dysfunction, 30% atrioventricular block). ALPs were implanted predominantly in the right atrial appendage anterior base and VLPs primarily at the mid-to-apical right ventricular septum. From implant to 1 month, pacing capture thresholds (0.4-ms pulse width) improved in both ALPs (2.4 ± 1.5 V to 0.8 ± 0.8 V; P <.001) and VLPs (0.8 ± 0.6 V to 0.6 ± 0.4 V; P <.001). Sensed amplitudes improved in both ALPs (1.8 ± 1.3 mV to 3.4 ± 1.9 mV; P <.001) and VLPs (8.8 ± 4.0 mV to 11.7 ± 4.2 mV; P <.001). Impedances were stable in ALPs (334 ± 68 Ω to 329 ± 52 Ω; P = .17) and reduced in VLPs (789 ± 351 Ω to 646 ± 190 Ω; P <.001). Electrical measurements remained relatively stable from 1-6 months postimplant. No differences in electrical metrics were observed among ALP or VLP implant locations. CONCLUSION: This first in-human evaluation of the new dual-chamber leadless pacemaker system demonstrated reliable electrical performance throughout the initial 6-month evaluation period.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25004081
003      
CZ-PrNML
005      
20250206105122.0
007      
ta
008      
250121s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.hrthm.2024.04.091 $2 doi
035    __
$a (PubMed)38697271
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Hindricks, Gerhard $u Deutsches Herzzentrum der Charite, Berlin, Germany
245    10
$a Six-month electrical performance of the first dual-chamber leadless pacemaker / $c G. Hindricks, R. Doshi, P. Defaye, DV. Exner, VY. Reddy, RE. Knops, R. Canby, M. Shoda, MG. Bongiorni, P. Neužil, T. Callahan, S. Sundaram, N. Badie, JE. Ip
520    9_
$a BACKGROUND: The first dual-chamber leadless pacemaker (DC-LP) system consists of 2 separate atrial and ventricular devices that communicate to maintain synchronous atrioventricular pacing and sensing. The initial safety and efficacy were previously reported. OBJECTIVE: The purpose of this study was to evaluate the chronic electrical performance of the DC-LP system. METHODS: Patients meeting standard dual-chamber pacing indications were enrolled and implanted with the DC-LP system (Aveir DR, Abbott), including right atrial and ventricular helix-fixation LPs (atrial leadless pacemaker [ALP], ventricular leadless pacemaker [VLP]). Pacing capture threshold, sensed amplitude, and pacing impedance were collected using the device programmer at prespecified timepoints from 0-6 months postimplant. RESULTS: De novo devices were successfully implanted in 381 patients with complete 6-month data (62% male; age 69 ± 14 years; weight 82 ± 20 kg; 65% sinus nodal dysfunction, 30% atrioventricular block). ALPs were implanted predominantly in the right atrial appendage anterior base and VLPs primarily at the mid-to-apical right ventricular septum. From implant to 1 month, pacing capture thresholds (0.4-ms pulse width) improved in both ALPs (2.4 ± 1.5 V to 0.8 ± 0.8 V; P <.001) and VLPs (0.8 ± 0.6 V to 0.6 ± 0.4 V; P <.001). Sensed amplitudes improved in both ALPs (1.8 ± 1.3 mV to 3.4 ± 1.9 mV; P <.001) and VLPs (8.8 ± 4.0 mV to 11.7 ± 4.2 mV; P <.001). Impedances were stable in ALPs (334 ± 68 Ω to 329 ± 52 Ω; P = .17) and reduced in VLPs (789 ± 351 Ω to 646 ± 190 Ω; P <.001). Electrical measurements remained relatively stable from 1-6 months postimplant. No differences in electrical metrics were observed among ALP or VLP implant locations. CONCLUSION: This first in-human evaluation of the new dual-chamber leadless pacemaker system demonstrated reliable electrical performance throughout the initial 6-month evaluation period.
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    12
$a kardiostimulátor $7 D010138
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a senioři $7 D000368
650    12
$a kardiostimulace umělá $x metody $7 D002304
650    12
$a design vybavení $7 D004867
650    _2
$a následné studie $7 D005500
650    _2
$a výsledek terapie $7 D016896
650    _2
$a srdeční komory $x patofyziologie $7 D006352
650    _2
$a atrioventrikulární blokáda $x terapie $x patofyziologie $7 D054537
650    _2
$a časové faktory $7 D013997
650    _2
$a syndrom chorého sinu $x terapie $x patofyziologie $7 D012804
655    _2
$a časopisecké články $7 D016428
700    1_
$a Doshi, Rahul $u HonorHealth Cardiac Arrhythmia Group, Scottsdale, Arizona
700    1_
$a Defaye, Pascal $u Centre Hospitalier Universitaire Grenoble Alpes, Grenoble, France
700    1_
$a Exner, Derek V $u Foothills Medical Centre, Calgary, Canada
700    1_
$a Reddy, Vivek Y $u Mount Sinai Fuster Heart Hospital, New York, New York
700    1_
$a Knops, Reinoud E $u Amsterdam UMC, Amsterdam, The Netherlands
700    1_
$a Canby, Robert $u Texas Cardiac Arrhythmia Institute, Austin, Texas
700    1_
$a Shoda, Morio $u Tokyo Women's Medical University, Tokyo, Japan
700    1_
$a Bongiorni, Maria Grazia $u San Rossore Private Hospital and Medical Center, Pisa, Italy
700    1_
$a Neužil, Petr $u Na Homolce Hospital, Prague, Czech Republic
700    1_
$a Callahan, Thomas $u Cleveland Clinic Foundation, Cleveland, Ohio
700    1_
$a Sundaram, Sri $u South Denver Cardiology, Littleton, Colorado
700    1_
$a Badie, Nima $u Abbott, Sylmar, California
700    1_
$a Ip, James E $u Weill Cornell Medicine/New York Presbyterian Hospital, New York, New York. Electronic address: jei9008@med.cornell.edu
773    0_
$w MED00156180 $t Heart rhythm $x 1556-3871 $g Roč. 21, č. 10 (2024), s. 1929-1938
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38697271 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250121 $b ABA008
991    __
$a 20250206105117 $b ABA008
999    __
$a ok $b bmc $g 2263686 $s 1240088
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 21 $c 10 $d 1929-1938 $e 20240430 $i 1556-3871 $m Heart rhythm $n Heart Rhythm $x MED00156180
LZP    __
$a Pubmed-20250121

Find record

Citation metrics

Archiving options